Jafari Salim Shirin, Alizadeh Shahab, Djalali Mahmoud, Nematipour Ebrahim, Hassan Javanbakht Mohammad
1 Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
2 Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Am J Mens Health. 2017 Nov;11(6):1758-1764. doi: 10.1177/1557988317720581. Epub 2017 Aug 21.
Adipokines are mediators of body composition and are involved in obesity-related complications such as cardiovascular disease. Omega-3 supplementation has not been studied in the setting of body composition and follistatin-like 1 (FSTL1) levels in patients with coronary artery disease (CAD). This study aimed to investigate the effect of omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation on body composition indices and serum levels of FSTL1 in CAD patients. A total of 42 male (aged 45-65 years) subjects with angiographically confirmed CAD were included in this randomized, double-blind, placebo-controlled trial study. The subjects were randomly divided into omega-3 and placebo groups. During the 8-week intervention, the omega-3 group received 1,200 mg of omega-3 daily, while the placebo group received paraffin. Before and after the study, anthropometric measurements and body composition components were taken; serum FSTL1 levels were assessed by an enzyme-linked immunosorbent assay (ELISA) kit. In the omega-3 group, a significant 27.6% increase in serum FSTL1 was seen after 8 weeks of intervention ( p = .001), but no significant difference in posttreatment levels of FSTL1 was observed between the two groups ( p > .05). At the end of the study, a significant decrease in low-density lipoprotein cholesterol (LDL-C; 94.29 ± 22.04 vs. 112.24 ± 24.5; p = .01) and high-sensitivity C-reactive protein (hs-CRP; 1.92 ± 0.79 vs. 3.19 ± 2.51; p = .03) concentration was detected between the two groups. Changes in fasting blood sugar, fasting insulin, body composition, and anthropometric parameters were not significant within and between the groups. Oral omega-3 might increase FSTL1 and decrease LDL-C and hs-CRP concentrations in CAD patients. However, omega-3 supplementation did not have any effect on FSTL1 levels between the groups.
脂肪因子是身体成分的介质，参与肥胖相关并发症，如心血管疾病。在冠状动脉疾病（CAD）患者的身体成分和卵泡抑素样蛋白1（FSTL1）水平方面，尚未对补充ω-3进行研究。本研究旨在探讨补充ω-3多不饱和脂肪酸（ω-3 PUFA）对CAD患者身体成分指标和血清FSTL1水平的影响。本项随机、双盲、安慰剂对照试验研究共纳入42名经血管造影证实患有CAD的男性（年龄45 - 65岁）受试者。受试者被随机分为ω-3组和安慰剂组。在为期8周的干预期间，ω-3组每天接受1200毫克ω-3，而安慰剂组接受石蜡。在研究前后，进行人体测量和身体成分分析；血清FSTL1水平通过酶联免疫吸附测定（ELISA）试剂盒进行评估。在ω-3组中，干预8周后血清FSTL1显著增加27.6%（p = 0.001），但两组之间FSTL1的治疗后水平未观察到显著差异（p > 0.05）。在研究结束时，两组之间检测到低密度脂蛋白胆固醇（LDL-C；94.29±22.04 vs. 112.24±24.5；p = 0.01）和高敏C反应蛋白（hs-CRP；1.92±0.79 vs. 3.19±2.51；p = 0.03）浓度显著降低。空腹血糖、空腹胰岛素、身体成分和人体测量参数在组内和组间的变化均不显著。口服ω-3可能会增加CAD患者的FSTL1，并降低LDL-C和hs-CRP浓度。然而，补充ω-3对两组之间的FSTL1水平没有任何影响。
